NCT06863818Active, not recruiting
Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs
Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs (Superamento Della Resistenza Alla Neutralizzazione di EGFR Nel Trattamento Con Anticorpi Monoclonali e Nuovi Farmaci Oncologici)
Source: ClinicalTrials.gov · Last updated 7 Mar 2025
Brief summary (registry, in English)
The study is aimed at patients with advanced cancer and EGFR mutation. Some molecules recently discovered at the level of tumor tissue can influence the response to anti-EGFR drugs. Among these molecules is NRG1, which binds to the EGFR receptor family. Unravelling the mechanisms that give cancer cells resistance to such biologics could improve response to therapy and survival. And analyzing tumors during anti-EGFR drug therapy used in clinical practice could allow us to perform analyses on NRG1 and hypothesize a possible strategy to increase survival
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 10 Jan 2025
- Start date
- 10 Oct 2022
- Primary completion date
- 31 Mar 2024
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Diseases
- Lung cancer
- NCT number
- NCT06863818
What you commit to
- Study type: Observational
- Planned participants: 30
- From 10 Oct 2022 to the primary completion date, 31 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- patients suffering from pathologies (e.g. psychiatric, neurological) that do not allow the obtaining of valid informed consent
Other
- Patients who in the opinion of the investigator may not be compliant with the needs of the study
Who the study is looking for
- patients aged ≥ 18 years
- patients with advanced cancer characterized by amplification/overexpression or activating mutations of the EGFR receptor.
- patients who are candidates for treatment with TKI and/or mAbs both in the first and second line, according to clinical practice.
- possibility of obtaining all information relating to the clinical history - obtaining written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna Coordinator of this site? Confirm its status | Bologna | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.